FDA Drug recall D-0093-2022
Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only
- FDA Drug
- Class I
- terminated
- Published 2021-11-10
On 2021-11-10 the FDA classified a Class I recall of Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only by Merck Sharp And Dohme, citing presence of Particulate Matter: Identified as Glass Particles.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0093-2022 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2021-10-19 |
| Published | 2021-11-10 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Merck Sharp And Dohme |
| Distribution | US |
Product
Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01
Reason
Presence of Particulate Matter: Identified as Glass Particles
Identifiers
| code_info | Lot #: 934778, Exp. Date Jun 2022 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0093-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.